My ePortfolio Register   

Risk of serious and fatal adverse events with sorafenib use in patients with solid cancers

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.10.16
Views: 1848
Rating:

Dr Bishal Gyawali - Nagoya University, Nagoya, Japan

Dr Gyawali meets with ecancertv at ESMO 2016 to discuss the safety profile of sorafenib, with a 27% increase in the risk of grade 4 and 5 adverse events compared to standard care.

He describes the context of the results from this meta-analysis, considering the balancing of risk and outcome for patients, and the impact of treatment-related hospitalisation on quality of life.

Dr Gyawali spoke further with ecancer about his upcoming publication in ecancers' medical journal, coming soon, and contributes a regular blog with his views on recent research.

 

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence